Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the recipient of a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 1,714,947 shares, a decrease of 58.9% from the July 30th total of 4,168,511 shares. Based on an average daily volume of 683,553 shares, the days-to-cover ratio is currently 2.5 days. Currently, 3.6% of the shares of the company are short sold.

Theravance Biopharma Price Performance

TBPH opened at $17.05 on Friday. Theravance Biopharma has a 12 month low of $13.08 and a 12 month high of $21.03. The business has a 50-day moving average of $16.96 and a two-hundred day moving average of $16.63. The stock has a market capitalization of $885.24 million, a price-to-earnings ratio of 16.88 and a beta of 0.19.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.18). The company had revenue of $20.73 million during the quarter, compared to analyst estimates of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. Equities research analysts anticipate that Theravance Biopharma will post 1.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. HC Wainwright cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $15.00 to $17.00 in a research note on Tuesday, July 7th. Finally, Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $19.40.

Insiders Place Their Bets

In other news, major shareholder Eli Samaha sold 37,799 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the sale, the insider directly owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. This represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the sale, the senior vice president directly owned 232,457 shares of the company’s stock, valued at $3,809,970.23. The trade was a 5.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in Theravance Biopharma during the first quarter valued at approximately $2,076,000. Wedge Capital Management L L P NC purchased a new position in shares of Theravance Biopharma in the 2nd quarter valued at $2,190,000. Precision Wealth Strategies LLC purchased a new position in shares of Theravance Biopharma in the 1st quarter valued at $1,019,000. Dimensional Fund Advisors LP lifted its holdings in shares of Theravance Biopharma by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 124,658 shares in the last quarter. Finally, UBS Group AG lifted its holdings in shares of Theravance Biopharma by 10.9% during the 4th quarter. UBS Group AG now owns 570,425 shares of the biopharmaceutical company’s stock valued at $10,673,000 after acquiring an additional 56,255 shares in the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.